NCT03815890View on ClinicalTrials.gov

Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO

PHASE2RecruitingINTERVENTIONAL

Enrollment

80

Participants

Timeline

Start Date

October 4, 2019

Primary Completion Date

January 1, 2031

Study Completion Date

January 1, 2033

Conditions

Breast Cancer

Interventions

DRUG

Nivolumab

2 courses 240 mg flat dose

DRUG

Ipilimumab

single dose ipilimumab (1mg/kg) at day 1

DRUG

Ipilimumab

two courses ipilimumab (1mg/kg) at day 1 and 21

Trial Locations (1)

1066CX

RECRUITING

NKI-AVL, Amsterdam

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

The Netherlands Cancer Institute

OTHER

NCT03815890 - Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO | Biotech Hunter | Biotech Hunter